A study of MN-166 for the treatment of Krabbe disease

Trial Profile

A study of MN-166 for the treatment of Krabbe disease

Planning
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2016

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Globoid cell leukodystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2016 The US FDA has granted Rare Pediatric Disease Designation to MN-166 (ibudilast) for treatment of Type 1-early infantile Krabbe disease, according to a Medicinova media release.
    • 04 Jun 2015 New trial record
    • 03 Jun 2015 MediciNova received an orphan-drug designation for MN-166 for Krabbe Disease and plans to finalize and submit the protocol of this study to the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top